Top

Published in:

01-04-2022 | Central Nervous System Trauma | Original Communication

Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019

Authors: Alberto Raggi, Lorenzo Monasta, Ettore Beghi, Valeria Caso, Giulio Castelpietra, Stefania Mondello, Giorgia Giussani, Giancarlo Logroscino, Francesca Giulia Magnani, Marco Piccininni, Elisabetta Pupillo, Stefano Ricci, Luca Ronfani, Paola Santalucia, Davide Sattin, Silvia Schiavolin, Claudia Toppo, Eugenio Traini, Jaimie Steinmetz, Emma Nichols, Rui Ma, Theo Vos, Valery Feigin, Matilde Leonardi

Published in: Journal of Neurology | Issue 4/2022

Abstract

Background

Neurological conditions are highly prevalent and disabling, in particular in the elderly. The Italian population has witnessed sharp ageing and we can thus expect a rising trend in the incidence, prevalence and disability of these conditions.

Methods

We relied on the Global Burden of Disease 2019 study to extract Italian data on incidence, prevalence and years lived with a disability (YLDs) referred to a broad set of neurological disorders including, brain and nervous system cancers, stroke, encephalitis, meningitis, tetanus, traumatic brain injury, and spinal cord injury. We assessed changes between 1990 and 2019 in counts and age-standardized rates.

Results

The most prevalent conditions were tension-type headache, migraine, and dementias, whereas the most disabling were migraine, dementias and traumatic brain injury. YLDs associated with neurological conditions increased by 22.5%, but decreased by 2.3% in age-standardized rates. The overall increase in prevalence and YLDs counts was stronger for non-communicable diseases with onset in old age compared to young to adult-age onset ones. The same trends were in the opposite direction when age-standardized rates were taken into account.

Conclusions

The increase in YLDs associated with neurological conditions is mostly due to population ageing and growth: nevertheless, lived disability and, as a consequence, impact on health systems has increased. Actions are needed to improve outcome and mitigate disability associated with neurological conditions, spanning among diagnosis, treatment, care pathways and workplace interventions.

Available only for authorised users

GBD 2019 Diseases and Injuries Collaborators (2020) Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9CrossRef

GBD 2016 Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459–480. https://doi.org/10.1016/S1474-4422(18)30499-XCrossRef

Deuschl G, Beghi E, Fazekas F, Varga T, Christoforidi KA, Sipido E, Bassetti CL, Vos T, Feigin VL (2020) The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health 5(10):e551–e567. https://doi.org/10.1016/S2468-2667(20)30190-0CrossRefPubMed

Raggi A, Leonardi M (2020) Burden of brain disorders in Europe in 2017 and comparison with other non-communicable disease groups. J Neurol Neurosurg Psychiatry 91(1):104–105. https://doi.org/10.1136/jnnp-2019-320466CrossRefPubMed

Mazzola P, Rimoldi SM, Rossi P, Noale M, Rea F, Facchini C, Maggi S, Corrao G, Annoni G (2016) Aging in Italy: the need for new welfare strategies in an old country. Gerontologist 56(3):383–390. https://doi.org/10.1093/geront/gnv152CrossRefPubMed

Italian National Institute for Statistics (2011) Il futuro demografico del Paese. Previsioni regionali della popolazione residente al 2065. Statistiche report, 1–12. https://www.istat.it/it/archivio/48875 Accessed 28 Jul 2021

Reher DS (2015) Baby booms, busts, and population ageing in the developed world. Popul Stud (Camb) 69(Suppl 1):S57-68. https://doi.org/10.1080/00324728.2014.963421CrossRef

GBD 2019 Demographics Collaborators (2020) Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1160–1203. https://doi.org/10.1016/S0140-6736(20)30977-6CrossRef

Salomon JA, Haagsma JA, Davis A, de Noordhout CM, Polinder S, Havelaar AH, Cassini A, Devleesschauwer B, Kretzschmar M, Speybroeck N, Murray CJ, Vos T (2015) Disability weights for the Global Burden of Disease 2013 study. Lancet Glob Health 3:e712–e723. https://doi.org/10.1016/S2214-109X(15)00069-8CrossRefPubMed

10.

Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 55(1):3–20. https://doi.org/10.1111/head.12499CrossRefPubMed

11.

Sprenger T, Viana M, Tassorelli C (2018) Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics 15(2):313–323. https://doi.org/10.1007/s13311-018-0621-8CrossRefPubMedPubMedCentral

12.

D’Onofrio F, Raimo S, Spitaleri D, Casucci G, Bussone G (2017) Usefulness of nutraceuticals in migraine prophylaxis. Neurol Sci 38(Suppl 1):117–120. https://doi.org/10.1007/s10072-017-2901-1CrossRefPubMed

13.

Puledda F, Goadsby PJ (2017) An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache 57(4):685–691. https://doi.org/10.1111/head.13069CrossRefPubMed

14.

Raggi A, Grignani E, Leonardi M, Andrasik F, Sansone E, Grazzi L, D’Amico D (2018) Beavioral approaches for primary headaches: recent advances. Headache 58(6):913–925. https://doi.org/10.1111/head.13337CrossRefPubMed

15.

Belvís R, Irimia P, Pozo-Rosich P, González-Oria C, Cano A, Viguera J, Sánchez B, Molina F, Beltrán I, Oterino A, Cuadrado E, Gómez-Camello A, Alberte-Woodward M, Jurado C, Oms T, Ezpeleta D, de Terán JD, Morollón N, Latorre G, Torres-Ferrús M, Alpuente A, Lamas R, Toledano C, Leira R, Santos S, Del Río MS (2021) MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. J Headache Pain 22(1):74. https://doi.org/10.1186/s10194-021-01267-xCrossRefPubMedPubMedCentral

16.

Ashina M, Cohen JM, Galic M, Campos VR, Barash S, Ning X, Kessler Y, Janka L, Diener HC (2021) Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2–4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain 22(1):68. https://doi.org/10.1186/s10194-021-01279-7CrossRefPubMedPubMedCentral

17.

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https://doi.org/10.1186/s10194-021-01247-1CrossRefPubMedPubMedCentral

18.

Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA (2021) Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol 21(1):126. https://doi.org/10.1186/s12883-021-02123-wCrossRefPubMedPubMedCentral

19.

Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S (2021) Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain 22(1):5. https://doi.org/10.1186/s10194-020-01214-2CrossRefPubMedPubMedCentral

20.

Schroeder RA, Brandes J, Buse DC, Calhoun A, Eikermann-Haerter K, Golden K, Halker R, Kempner J, Maleki N, Moriarty M, Pavlovic J, Shapiro RE, Starling A, Young WB, Nebel RA (2018) Sex and gender differences in migraine-evaluating knowledge gaps. J Womens Health (Larchmt) 27(8):965–973. https://doi.org/10.1089/jwh.2018.7274CrossRef

21.

Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people’s life. J Headache Pain 20(1):41. https://doi.org/10.1186/s10194-019-0993-0CrossRefPubMedPubMedCentral

22.

GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954–976. https://doi.org/10.1016/S1474-4422(18)30322-3CrossRef

23.

Rota E, Zucco R, Guerzoni S, Cainazzo MM, Pini LA, Catarci T, Granella F (2020) Migraine awareness in Italy and the myth of “cervical arthrosis.” Headache 60(1):81–89. https://doi.org/10.1111/head.13679CrossRefPubMed

24.

Cevoli S, D’Amico D, Martelletti P, Valguarnera F, Del Bene E, De Simone R, Sarchielli P, Narbone M, Testa L, Genco S, Bussone G, Cortelli P (2009) Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. Cephalalgia 29(12):1285–1293. https://doi.org/10.1111/j.1468-2982.2009.01874.xCrossRefPubMed

25.

Kwan P, Schachter SC, Brodie MJ (2011) Drug-resistant epilepsy. N Engl J Med 365:919–926. https://doi.org/10.1056/NEJMra1004418CrossRefPubMed

26.

Li MCH, Cook MJ (2018) Deep brain stimulation for drug-resistant epilepsy. Epilepsia 59(2):273–290. https://doi.org/10.1111/epi.13964CrossRefPubMed

27.

GBD 2016 Epilepsy Collaborators (2019) Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:357–735. https://doi.org/10.1016/S1474-4422(18)30454-XCrossRef

28.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral

29.

Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N (2017) Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry 88(8):621–625. https://doi.org/10.1136/jnnp-2016-315238CrossRefPubMed

30.

Kingwell E, van der Kop M, Zhao Y, Shirani A, Zhu F, Oger J, Tremlett H (2012) Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry 83(1):61–66. https://doi.org/10.1136/jnnp-2011-300616CrossRefPubMed

31.

Ragonese P, Aridon P, Mazzola MA, Callari G, Palmeri B, Famoso G, Terruso V, Salemi G, D’Amelio M, Savettieri G (2010) Multiple sclerosis survival: a population-based study in Sicily. Eur J Neurol 17(3):391–397. https://doi.org/10.1111/j.1468-1331.2009.02814.xCrossRefPubMed

32.

Mandel M, Mercier F, Eckert B, Chin P, Betensky RA (2013) Estimating time to disease progression comparing transition models and survival methods—an analysis of multiple sclerosis data. Biometrics 69(1):225–234. https://doi.org/10.1111/biom.12002CrossRefPubMedPubMedCentral

33.

Kalincik T, Diouf I, Sharmin S, Malpas C, Spelman T, Horakova D, Havrdova EK, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Jokubaitis V, van der Walt A, Grand’Maison F, Sola P, Ferraro D, Shaygannejad V, Alroughani R, Hupperts R, Terzi M, Boz C, Lechner-Scott J, Pucci E, Van Pesch V, Granella F, Bergamaschi R, Spitaleri D, Slee M, Vucic S, Ampapa R, McCombe P, Ramo-Tello C, Prevost J, Olascoaga J, Cristiano E, Barnett M, Saladino ML, Sanchez-Menoyo JL, Hodgkinson S, Rozsa C, Hughes S, Moore F, Shaw C, Butler E, Skibina O, Gray O, Kermode A, Csepany T, Singhal B, Shuey N, Piroska I, Taylor B, Simo M, Sirbu CA, Sas A, Butzkueven H, MSBase Study Group (2021) effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years. Neurology 96(5):e783–e797. https://doi.org/10.1212/WNL.0000000000011242CrossRefPubMedPubMedCentral

34.

Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand’Maison F, Terzi M, Lechner-Scott J, Flechter S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scolding N, Wilkins A, Pearson OR, Ziemssen T, Hutchinson M, Harding K, Jones J, McGuigan C, Butzkueven H, Kalincik T, Robertson N, MSBase Study Group (2019) Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 321(2):175–187. https://doi.org/10.1001/jama.2018.20588CrossRefPubMedPubMedCentral

35.

Jobin C, Larochelle C, Parpal H, Coyle PK, Duquette P (2010) Gender issues in multiple sclerosis: an update. Womens Health (Lond) 6(6):797–820. https://doi.org/10.2217/whe.10.69CrossRef

36.

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA, Italian Multiple Sclerosis Register Centers Group (2019) The Italian Multiple Sclerosis Register. Neurol Sci 40(1):155–165. https://doi.org/10.1007/s10072-018-3610-0CrossRefPubMed

37.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N (2017) Dementia prevention, intervention, and care. Lancet 390(10113):2673–2734. https://doi.org/10.1016/S0140-6736(17)31363-6CrossRefPubMed

38.

GBD 2016 Brain and Other CNS Cancer Collaborators (2019) Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:376–393. https://doi.org/10.1016/S1474-4422(18)30468-XCrossRef

39.

GBD 2016 Motor Neuron Disease Collaborators (2016) Global, regional, and national burden of motor neuron diseases 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:1083–1097. https://doi.org/10.1016/S1474-4422(18)30404-6CrossRef

40.

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, Ogunbiyi OJ, Azevedo-E-Silva G, Chen WQ, Eser S, Engholm G, Stiller CA, Monnereau A, Woods RR, Visser O, Lim GH, Aitken J, Weir HK, Coleman MP, CONCORD Working Group (2018) Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391:1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3CrossRefPubMedPubMedCentral

41.

Ferroli P, Schiariti M, Finocchiaro G, Salmaggi A, Castiglione M, Acerbi F, Tringali G, Farinotti M, Broggi M, Roberto C, Maccagnano E, Broggi G (2013) Operability of glioblastomas: “sins of action” versus “sins of non-action.” Neurol Sci 34(12):2107–2116. https://doi.org/10.1007/s10072-013-1345-5CrossRefPubMed

42.

Sheers N, Berlowitz DJ, Rautela L, Batchelder I, Hopkinson K, Howard ME (2014) Improved survival with an ambulatory model of non-invasive ventilation implementation in motor neuron disease. Amyotroph Lateral Scler Frontotemporal Degener 15(3–4):180–184. https://doi.org/10.1007/s10072-013-1345-5CrossRefPubMed

43.

Albrechtsen SS, Born AP, Boesen MS (2020) Nusinersen treatment of spinal muscular atrophy - a systematic review. Dan Med J 67(9):A02200100PubMed

44.

GB D 2016 Parkinson’s Disease Collaborators (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939–953. https://doi.org/10.1016/S1474-4422(18)30295-3CrossRef

45.

Sabatino M (2016) The de-industrialization process in South Italy and the new industrial policies in Europe. European Regional Science Association (ERSA) 2016 conference papers ersa16p885. https://ideas.repec.org/p/wiw/wiwrsa/ersa16p885.html Accessed 28 Jul 2021

46.

Hill VA, Towfighi A (2017) Modifiable risk factors for stroke and strategies for stroke prevention. Semin Neurol 37(3):237–258. https://doi.org/10.1055/s-0037-1603685CrossRefPubMed

47.

Coppo A, Baldissera S, Migliardi A, Minardi V, Quarchioni E, Ferrante G, Dal Molin A, Faggiano F, PASSI Working Group (2017) Quit attempts and smoking cessation in Italian adults (25–64 years): factors associated with attempts and successes. Eur J Public Health 27(4):717–722. https://doi.org/10.1093/eurpub/ckw262CrossRefPubMed

48.

Leone A, Battezzati A, De Amicis R, De Carlo G, Bertoli S (2017) Trends of adherence to the Mediterranean dietary pattern in northern Italy from 2010 to 2016. Nutrients 9(7):734. https://doi.org/10.3390/nu9070734CrossRefPubMedCentral

49.

Servadei F, Ciucci G, Piazza G, Bianchedi G, Rebucci G, Gaist G, Taggi F (1988) A prospective clinical and epidemiological study of head injuries in Northern Italy: the Commune of Ravenna. Ital J Neurol Sci 9:449–457CrossRef

50.

Baldo V, Marcolongo A, Floreani A, Majori S, Cristofoletti M, Dal Zotto A, Vazzoler G, Trivello R (2003) Epidemiological aspect of traumatic brain injury in Northeast Italy. Eur J Epidemiol 18:1059–1063. https://doi.org/10.1023/a:1026192020963CrossRefPubMed

51.

Barker-Collo SL, Feigin VL (2009) Capturing the spectrum: suggested standards for conducting population-based traumatic brain injury incidence studies. Neuroepidemiology 32:1–3. https://doi.org/10.1159/000170084CrossRefPubMed

52.

Barker-Collo S, Theadom A, Jones K, Feigin VL, Kahan M (2016) Accuracy of an International Classification of Diseases code surveillance system in the identification of traumatic brain injury. Neuroepidemiology 47:46–52. https://doi.org/10.1159/000448403CrossRefPubMed

53.

Ferro S, Cecconi L, Bonavita J, Pagliacci MC, Biggeri A, Franceschini M (2017) Incidence of traumatic spinal cord injury in Italy during 2013–2014: a population-based study. Spinal Cord 55(12):1103–1107. https://doi.org/10.1038/sc.2017.88CrossRefPubMed

54.

GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators (2019) Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(1):56–87. https://doi.org/10.1016/S1474-4422(18)30415-0CrossRef

55.

GBD 2016 Meningitis Collaborators (2018) Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(12):1061–1082. https://doi.org/10.1016/S1474-4422(18)30387-9CrossRef

56.

GB D 2015 Neurological Disorders Collaborator Group (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16:877–897. https://doi.org/10.1016/S1474-4422(17)30299-5CrossRef

57.

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2CrossRef

58.

Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548–1554. https://doi.org/10.1212/WNL.0b013e3181a41211CrossRefPubMed

59.

Damian MS, Ben-Shlomo Y, Howard R, Bellotti T, Harrison D, Griggs K, Rowan K (2013) The effect of secular trends and specialist neurocritical care on mortality for patients with intracerebral haemorrhage, myasthenia gravis and Guillain-Barré syndrome admitted to critical care: an analysis of the Intensive Care National Audit and Research Centre (ICNARC) national United Kingdom database. Intensive Care Med 39(8):1405–1412. https://doi.org/10.1007/s00134-013-2960-6CrossRefPubMed

60.

Ruiz E, Ramalle-Gómara E, Quiñones C, Martínez-Ochoa E (2016) Trends in Guillain–Barré syndrome mortality in Spain from 1999 to 2013. Int J Neurosci 126(11):985–988. https://doi.org/10.3109/00207454.2015.1090437CrossRefPubMed

Title: Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019
Authors: Alberto Raggi
Lorenzo Monasta
Ettore Beghi
Valeria Caso
Giulio Castelpietra
Stefania Mondello
Giorgia Giussani
Giancarlo Logroscino
Francesca Giulia Magnani
Marco Piccininni
Elisabetta Pupillo
Stefano Ricci
Luca Ronfani
Paola Santalucia
Davide Sattin
Silvia Schiavolin
Claudia Toppo
Eugenio Traini
Jaimie Steinmetz
Emma Nichols
Rui Ma
Theo Vos
Valery Feigin
Matilde Leonardi
Publication date: 01-04-2022
Publisher: Springer Berlin Heidelberg
Keywords: Central Nervous System Trauma
Multiple Sclerosis
Migraine
Stroke
Dementia
Tension Headache
Dementia
Published in: Journal of Neurology / Issue 4/2022
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-021-10774-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2022

The effect and safety of levodopa alone versus levodopa sparing therapy for early Parkinson’s disease: a systematic review and meta-analysis

Early anticoagulation in atrial fibrillation-related acute ischaemic stroke: efficacy and safety profile

James Samuel Risien Russell (1863–1939)

Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study

Long-term outcome in patients with myasthenia gravis: one decade longitudinal study

Does visuospatial motion perception correlate with coexisting movement disorders in Parkinson’s disease?